Ygalo Continues to Show Positive Results in RRMM Patients, Oncopeptides Announces
Combination treatment with Ygalo (melflufen) continues to…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
AbbVie Obtains Global Rights Option for HPN217, Phase 1/2 Trial in Multiple Myeloma Planned
Harpoon Therapeutics has granted AbbVie an option for…
BiCNU Generic for Multiple Myeloma, Other Cancers Launched in US
Carmustine for Injection, a generic version of the…
Darzalex Triple Combo Approved in Europe for Myeloma Patients Ineligible for ASCT
The European Commission has approved Darzalex (daratumumab), in combination with …
First Multiple Myeloma Patient Dosed With CAR T-Cell Therapy UCARTCS1 in Phase 1 Trial
The donor-derived, or allogeneic CAR T-cell therapy candidate…
Ninlaro Prolongs Progression-free Survival in Multiple Myeloma Patients Not Given ASCT, Phase 3 Trial Shows
First-line maintenance therapy with Ninlaro (ixazomib) prolongs…
